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Positron computed tomography is a new method for the
external quantification of regional myocardial blood flow,
substrate fluxes and biochemical reaction rates. It takes
advantage of positron emitting tracers, metabolically ac-
tive tracers, tracer kinetic principles and the quantita-
tive imaging capabilities of the tomograph. To date, the
technique has been used primarily for the study of
ischemic heart disease and cardiomyopathies in adults.
However, initial studies in infants and adolescents with
regional cardiomyopathies provide evidence for its po-
tential value in detecting disease at the biochemical level
or at a stage that antedates clinical manifestations and
cardiac dysfunction. Positron computed tomography is
likely to contribute to our understanding of metabolic
abnormalities associated with cyanotic or congenital heart
disease and of the heart's maturation, and may become
Positron computed tomography is a unique tool for the non-
invasive study of regional myocardial function. Most at-
tractive is its ability to measure in vivo regional myocardial
metabolism. Its capability for quantitative imaging by using
labeled biologically active compounds and applying tracer
kinetic methods make it stand out among diagnostic radio-
nuclide techniques. Positron computed tomography relies
on the unique emission of two 511 keV photons in dia-
metrically opposed directions during positron annihilation,
registration and localization of the annihilation event by
coincidence detection, a unique electronic collimation and
accurate correction for photon attenuation. These physical
properties overcome the inherent difficulties limiting con-
ventional scintigraphy. The cross-sectional images produced
by the tomograph represent a quantitative measurement of
regional tissue tracer concentrations in the myocardium. For
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useful for optimal timing of corrective surgery. It allows
the study of intrinsic myocardial disease in children,
clarification of disease mechanisms and diagnosis of con-
genital metabolic disorders. It also might become useful
for detecting disease when it is still confined to biochem-
ical derangements and permit institution of therapy that
may halt progression or even reversal of disease before
irreversible morphologic changes develop. The high cost
of equipment purchase and operation has precluded
widespread use, but new technologic developments may
make it possible to perform these studies at a cost com-
parable with that of other noninvasive procedures. Pos-
itron computed tomography may then become available
as a routine diagnostic tool for studying pediatric cardiac
disorders.
(} Am Coli CardioI1985;5:140S-9S)
more technical detail, the reader is referred to several ex-
cellent recent reviews (l,2). Tissue tracer coricentrations
are calculated from regions of interest that encompass a
known volume and are communicated as mass of tracer per
gram tissue.
The physiologic tracers used in positron computed tom-
ographic metabolic studies are labeled with positron-emit-
ting isotopes of elements that are abundantly present in
nature. Oxygen-I5, nitrogen-13, carbon-II and fluorine-I 8
are used most commonly. The radioactive tracers are bio-
chemically indistinguishable from their parent substances.
Positron computed tomographic tracer uptake and turnover
rates in tissue regions are used to determine the rate of the
physiologic process under study through use of an opera-
tional equation derived from a tracer kinetic model of the
tissue metabolism. This approach provides measurements
of blood flow in ml/min per g tissue and of substrate trans-
port and metabolism in JLmol/min per g tissue. Thus, with
positron computed tomography, in vitro assay techniques
can be transferred in vivo safely and noninvasively and,
therefore, into human subjects.
Most of our present knowledge on myocardial metabo-
lism derives from in vitro experiments in isolated hearts and
cell preparations or from highly destructive animal exper-
iments (3). The study of regional metabolism in the human
heart, however, has remained elusive. This is now possible
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with positron computed tomography. Consequently, the ex-
istence of functional processes characterized and described
previously in the in vitro environment can now be directly
examined in patients. Equally important, this technology
can provide new insights into the physiology of the normal
and abnormal heart. Other techniques like echocardiog-
raphy, X-ray computed tomography and, more recently,
proton nuclear magnetic resonance imaging are or will be-
come important tools for examining the heart noninvasively.
The content of information obtained with these diagnostic
modes chiefly relates to structure and mechanical function.
Conventional radionuclide techniques similarly focus on
anatomy and function, but also render qualitative infor-
mation on regional myocardial blood flow. With its ability
to noninvasiveiy investigate in vivo human heart metabo-
lism, positron computed tomography goes a step beyond
these capabilities.
Measurements of Regional MetabOlic Rates
In addition to the quantitative capability of the imaging
device, the availability of biologically active tracers is equally
important in making metabolic measurements. Although the
number of tracer substances that can be labeled with posi-
tron-emitting isotopes appears virtually unlimited and more
than 200 have been synthesized to date, Table 1 lists only
those that have been evaluated for their utility in measuring
myocardial blood flow and metabolism. The specific activity
of these substances is high, and the mass required for studies
is, therefore, extremely small (local tissue concentrations
in the pico to nanomolar range or less). By definition, they
represent true tracers that do not perturb the process to be
studied. This is an important point with regard to nuclear
magnetic resonance imaging. Even for the in vitro nuclear
magnetic resonance spectroscopy of glucose metabolism,
the required mass of carbon-13 glucose is substantial. Tissue
concentrations of carbon-13 glucose in the range of 15 mM
are needed for nuclear magnetic resonance in animals (4).
The requirements for nuclear magnetic resonance imaging
in human subjects will be several orders of magnitude higher.
Effects of mass on the process under study and toxicity will
then become significant issues. In proton nuclear magnetic
resonance, for example, the hydrogen tissue concentration
is about 100 M.
Table 1. Positron-Emitting Tracers for Cardiac Evaluation
Radiophannaceutical
Blood flow
Gallium-68, copper-62 and carbon-I 1-
labeled albumin microspheres
Rubidium-82*
Nitrogen-13 ammonia
Metabolism
Glucose
Carbon-II glucose
Carbon-II methyl-D-glucose
Fluorine-I 8 2-fluoro 2-deoxyglucose
Free fatty acid
Carbon-II palmitic acid
Carbon-II beta-methyl-heptadecanoic
acid
Intermediate metabolism
Carbon-II acetic acid
Carbon-II pyruvic acid
Amino acids
Nitrogen-13 glutamate, alanine,
aspartate leucine, valine, methionine
Carbon-II aspartate leucine, glutamate,
valine, alanine, methyl-L-methionine,
phenylaline
Receptor ligands
Carbon-II methylquinuclinidyl benzylate
Carbon-II practolol
Physical Half-Time
(min) Comments
68.9.7,20A
1.3 *Generator-produced (strontium-82,
9.8 rubidium-82); both, rubidium-82
and nitrogen-I 3 ammonia are
administered intravenously
20A Natural compound
2004 Glucose analog, traces glucose
transport beiween blood and
myocardium
120.0 Traces initial transmembraneous
transport and glucose
phosphorylation
20 A Natural tracer
20 A Traces initial uptake of free fatty acid
and is retained in myocardium
20A Both of potential value for evaluating
2004 citric acid cycle activity
9.8 tSuitable for measurements of protein
synthesis
20A
20.4 Binds to muscarinic receptors
20A Binds to beta-adrenergic receptors
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Figure 1. Utilization ofexogenous glucose by canine myocardium
measured by the Fick method and the fluorine-I 8 2-fluoro 2-deox-
yglucose technique (denoted as MODEL) and positron computed
tomography. LC = lumped constant.
further validation and, if necessary, modification (12). Stud-
ies with this free fatty acid tracer have, therefore, remained
largely qualitative. Nevertheless, observations with this tracer
are in accord with available biochemical information and
have revealed some attractive and potentially important in-
sights into free fatty acid metabolism in the diseased heart.
In isolated perfused hearts, Nomura et al. (13) reported
a linear relation between tracer extraction fractions and steady
state extraction of palmitate from the perfusate. After ex-
traction, labeled palmitate clears from myocardial tissue in
a characteristically biexponential fashion as an expression
of the tracer distribution between at least two pools with
different turnover rates (14-17). Taken together with known
biochemical information and data derived from isolated per-
fused hearts and canine myocardium, this clearance pattern
reflects the distribution of free fatty acids between imme-
diate oxidation (the rapid turnover clearance phase) and
intermediate storage in the endogenous lipid pool (the slow
turnover clearance phase).
Increases in cardiac work and myocardial oxygen con-
sumption raise the fraction of tracer entering the rapid turn-
over pool and accelerate the clearance rate of carbon-II
activity from tissue (14,16,17), observations that reflect the
metabolic response to higher energy demands by augment-
ing oxidation of free fatty acid (Fig. 2). Conversely, acute
myocardial ischemia lowers or abolishes the fraction enter-
ing the rapid turnover pool and delays its clearance from
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Techniques for measuring regional physiologic processes
with positron computed tomography are generally developed
by determining the tissue response to a known input function
and its relation to the physiologic process under study. It
entails characterizing the kinetics of a given tracer in the
tissue under various physiologic conditions, relating these
kinetics to known biochemical information and formulating
a tracer kinetic model that describes the exchange of the
tracer and its reaction products among several functional
units (compartments of the model). Such tracer kinetic models
are simplified representations of complex physiologic pro-
cesses, yet they allow formulation of an operational equation
for calculating reaction rates and metabolic fluxes with a
remarkable degree of accuracy.
Determining glucose metabolism. Because free fatty
acids and glucose are the heart's major substrates for pro-
duction of high energy phosphates, investigations into tech-
niques for determining the metabolic rates of both substrates
have received considerable attention. Techniques for mea-
suring regional myocardial utilization rates of exogenous
glucose have advanced furthest and are best validated. Use
of carbon-II D-glucose is possible (5), but loss of labeled
metabolic intermediate and end products from the tissue
make the tracer kinetic model complex and susceptible to
significant modeling and measurement errors. To circum-
vent these difficulties, a competitive glucose analog, f1uo-
rine-I8 2-fluoro 2-deoxyglucose (FDG) has been employed
to measure exogenous glucose utilization rates. This glucose
analog competes with glucose for membrane carrier sites
and for hexokinase for phosphorylation to glucose-6-phos-
phate. However, the end product FDG-6-phosphate is not
a substrate for glycolysis, pentose shunt or glycogen syn-
thesis (6). Thus, this analog isolates the transport and phos-
phorylation reactions. The f1uorine-18 is slowly cleared from
tissue because of the low membrane permeability of FDG-
6-phosphate and the slow dephosphorylation reaction yield-
ing FDG (7). A tracer kinetic model originated by Sokoloff
et al. (6) for autoradiographic measurements of the local
metabolic rate of glucose in rat brain and subsequently mod-
ified by Phelps (7) and Huang (8) and coworkers for use
with positron computed tomography was adapted to the
heart. The validity of this three compartment tracer kinetic
model and, hence, of the measurement technique for use in
myocardium was confirmed in isolated perfused myocar-
dium (9), in canine hearts (to) and more recently in human
subjects (11). Values of regional rates of exogenous glucose
utilization derived with the technique agree well with Fick
measurements performed simultaneously in the isolated heart
(9) and in vivo in dogs (10) (Fig. I) or with those reported
for human subjects (11).
Determining free fatty acid metabolism. The study of
regional myocardial uptake and metabolism of free fatty
acids with carbon-II palmitic acid has been equally vig-
orous. A tracer kinetic model has been proposed but requires
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tracer tissue uptake and clearance (15,17,18-20). When free
fatty acids are used preferentially, a greater proportion of
carbon-II palmitic acid enters the oxidation pool as com-
pared with preferential glucose utilization when little if any
tracer is channeled into the oxidative pool (Fig. 3). This
occurs despite similar cardiac work loads and myocardial
oxygen consumption (16).
Determining other aspects of myocardial metabo-
lism. As indicated by the list of tracers in Table I, tech-
niques for examining other aspects of myocardial metabo-
lism are emerging. Measurements of citric acid cycle activity
with carbon-II acetic acid (21) or carbon-II pyruvic acid
seem feasible. Similarly, the availability of carbon-I 1- or
nitrogen-13-labeled amino acids will allow estimations of
participation of amino acids in intermediary energy metab-
olism as well as the measurement of protein synthesis (22,23).
Measurement of regional myocardial blood flow with
nitrogen-13 ammonia (24,25), rubidium-82 (26,27) or ox-
ygen-IS water (28,29) has been investigated. Although
hampered by current instrument-related limitations, such
measurements are likely to become available in the near
future as tomographic technology advances. Particularly at-
tractive is the oxygen-IS water method (already established
and used in the brain [30)) for rapid serial measurements
of regional myocardial blood flow, especially in combina-
tion with oxygen-IS oxygen for determining regional myo-
cardial oxygen consumption. The latter technique has been
extensively applied in the brain (30). Finally, work on de-
termining regional myocardial receptor density and dis-
placement of receptor ligands has only begun (31,32), but
promises to be of value in studying the heart's autonomic
nervous control as well as disease mechanisms.
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Figure 2. Fractional distribution and clearance of carbon-II pal-
mitic acid in human myocardium as a function of cardiac work.
The two studies were obtained in a patient with a rate program-
mable pacemaker after intravenous injection of carbon-II palmitic
acid and serial positron computed tomographic imaging. The dis-
played tissue time-activity curves were derived from regions of
interest assigned to the left ventricular myocardium. Note the biex-
ponential clearance pattern. In the control study with a heart rate
of 49 beats/min (bpm), extrapolation of the slow clearance phase
to the time of peak activity indicates that approximately 31 % of
the carbon-II palmitic acid entered the early rapid clearance phase
with a clearance half-time (T Ii2) of 24.1 minutes. As heart rate
(HR) was then increased to !OI beats/min (lower panel) while
blood pressure (BP) remained virtually the same and the positron
computed tomographic study was repeated, 62% of the carbon-II
palmitic acid entered the early rapid clearance phase and cleared
more rapidly from tissue.
tissue (15,17,19), an observation in accord with the known
impairment of free fatty acid oxidation in myocardial is-
chemia. Changes in substrate utilization, such as those caused
by altered substrate concentrations in plasma, also affect
Applications of Positron
Computed Tomography
Regionally or globally altered metabolism or inherent
metabolic defects are invariably present in human myo-
cardial disease. Clinically overt disease can originate with
a metabolic fault or, if initiated by injurious agents such as
viruses or toxins, can be caused by resultant biochemical
abnormalities that may ultimately lead to myonecrosis. Con-
versely, chronic disease processes lead to structural and
functional abnormalities, causing excessive energy demands
with often inadequate metabolic responses or metabolic mal-
adjustments. Good examples are dilated cardiomyopathies
or myocardial hypertrophy in response to increased cardiac
volume, increased pressure work or excessive adrenergic
stimulation. At the other end of the spectrum, delivery of
energy substrates and oxygen can be compromised (as in
coronary artery disease) and cause alterations in substrate
metabolism, initiation of compensatory changes and ulti-
mately cell death. These relations emphasize the central role
of metabolism in myocardial disease and the need for tech-
144S SCHELBERT ET AL.
POSITRON COMPUTED TOMOGRAPHY
JACC Vol. 5. No. I
January 1985: 140S-9S
40
R.G. No. S00207
T1/ 2 = 17.4 min
I I
20 30
MINUTES
AFTER ORAL GLUCOSE
54%
10
HR 70 bpm; BP 130/80 mmHg
o4010 20 30
MINUTES
FASTING
HR 68 bpm; BP 130/80 mmHg
39%
t T1/ 2 = 12.9 min
61%
~
1
-------
j
1'------+-----.,.---+----+---
o
2
3
4
6
20
30
z
o
I-
«
a:
I-
Z
W
U
Z
o
u ...... 10
w m::>!::
m Z
m::>
j:: I-
«
~ u
~ W
I .....
U
..J
«
o
a:
«
u
o
>-
:E
GLUCOSE 82 mg %
FFA 0.77 mEq/1
GLUCOSE 141 mg %
FFA 0.20 mEq/1
niques for examining regional myocardial metabolism, a
need that can now be met by positron computed tomography.
Practical alternative approaches do not exist.
To date, most investigations with positron computed to-
mography have been concerned with developing and vali-
dating technical aspects of performing cardiac studies (8-16).
Among these were characterization of tracer kinetics and
their relation to known biochemical information, as well as
actual configuration of tracer kinetic models and their testing
and validation so that biochemical reaction rates and sub-
strate fluxes could be determined. A logical extension of
these studies was to provide proof that positron computed
tomography provided measurements that were, indeed, ac-
curate and in accord with findings and measurements made
previously through invasive and often destructive means.
In parallel with these research endeavors were investigations
in adult cardiovascular disease producing new and provoc-
ative insights into the physiology and pathophysiology of
the heart (11,13,18,20,31,34-36,39,40).
Some of these observations are clinically relevant and
likely to influence disease management. For example, the
ability to detect mild and possibly subcritical coronary ste-
nosis was demonstrated first in dogs (33) and subsequently
in patients with coronary artery disease (34). Rapid serial
studies (35) with intravenous rubidium-82 in patients with
ischemic heart disease disclosed persistence of segmental
defects of tracer uptake long after the resolution of clinical
evidence of ischemia by electrocardiogram and angina. These
studies also revealed transient segmental reductions in tracer
uptake, even when chest pain or electrocardiographic changes
Figure 3. Effects of plasma substrate availability on the fractional
tissue distribution of carbon-II palmitic acid in a normal volunteer
studied after an overnight fast and again after oral glucose admin-
istration. Note the changes in plasma substrate concentrations listed
at the bottom, while heart rate (HR) and blood pressure (BP)
remained virtually the same during both studies. Nevertheless,
there was a marked change in the fractional tissue distribution and
clearance rate of carbon-II palmitic acid in myocardium. FFA =
free fatty acid; T1/2 = clearance half-time.
were absent, lending support to the notion of "silent is-
chemia. " Segmental reductions in tracer uptake in areas
afflicted by stress-induced ischemia could also be induced
by "mental stress" when patients were asked to perform
simple mathematical calculations, providing evidence for
an important role of the central nervous system in ischemic
heart disease (Selwyn AP, personal communication).
Combined use of tracers for blood flow and metabolism
permitted differentiation of infarcted from ischemic myo-
cardium (36), and the same technique can identify non-
functioning myocardial segments with residual though ab-
normal metabolic activity from those that have proceeded
to necrosis. Regardless of segmental function, utilization of
exogenous glucose in excess of blood flow or regional shifts
in substrate metabolism from free fatty acids to glucose seem
to indicate tissue salvageability and, after myocardial re-
perfusion, subsequent functional recovery (37). Metaboli-
cally active and, hence, viable tissue after reperfusion of
transiently ischemic canine myocardium was also charac-
terized noninvasively by increased extraction of carbon-II
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palmitic acid (38), In patients with subendocardial infarc-
tion, uneven uptake of the same tracer in myocardium un-
affected by the acute event was discovered and seemed to
signify metabolic sequelae of advanced coronary artery dis-
ease common in this particular patient group (39). Similar
observations have been made in patients with dilated car-
diomyopathy (40). In this case, heterogeneous myocardial
carbon-II palmitic acid uptake was seen as a reflection of
regionally disparate metabolic processes leading to myocytal
necrosis and fibrous tissue replacement (40). Last, patients
with depressed left ventricular function of various causes
exhibited abnormal free fatty acid utilization patterns that
were normalized by oral glucose administration (20).
Obviously, many of these observations await further elu-
cidation and mechanistic explanations. They do, however,
provide evidence for the ability to study disease at the met-
abolic level noninvasively, regionally and repeatedly during
the course of disease, with the patient at rest or after pro-
vocative interventions. Evaluation of drug effects is simi-
larly possible. Also, disease detection can be considerably
refined with this new technology, and new insights into
disease processes can be gained, such as the effects of men-
tal stress on ischemic heart disease, the presence of "silent
ischemia" or the existence of what might be defined as
"chronic ischemia."
The Study of Cardiovascular
Disease in the Young
There have been only a few studies using positron com-
puted tomography in infants and adolescents. Yet, exami-
nation of metabolic aspects of pediatric cardiac disease ap-
pears to be of interest. Metabolic defects can be either the
consequence or the cause of disease. The latter is of special
interest in pediatric studies. Disease that becomes clinically
apparent in adulthood may result from a chronically existing
biochemical derangement beginning in childhood or even
infancy. Detection near onset could have therapeutic con-
sequences. Maturation of the heart's metabolism is another
important aspect of potential pediatric studies. In addition
to improving our understanding of the heart's normal phys-
iology in children and infants, positron computed tomog-
raphy possesses the potential for making significant contri-
butions to the understanding and management of pediatric
cardiac disorders.
Congenital malformations. These represent a large
proportion of pediatric diseases, but their metabolic con-
sequences have remained largely unexplored. Chronic hypo-
oxygenation in cyanotic heart disease, for example, is likely
to affect cardiac metabolism. Whether it results in reversible
or irreversible damage is important in regard to surgical
correction of the malformation. Additionally, whether this
low level of oxygen is related to the observed incomplete
recovery of left ventricular function after surgical correction
of tetralogy of Fallot with a residual ventricular septal defect
or is related to an isolated ventricular septal defect (41)
could be determined. Other recent observations (42) raise
additional questions. Timing of surgical correction of con-
genital malformations conceptually would seem best as early
in life as possible. The outcome of surgical interventions
may, however, be influenced by the incomplete maturation
of the heart's metabolism in the neonate (42).
Cardiomyopathy. This is another potentially important
area of investigation. Although viral infections are thought
to be most often the culprit of dilated forms of cardio-
myopathy, the cause of other forms has remained obscure.
Metabolic defects have been established as a cause in some.
Carnitine or palmityl transferase deficiency or ketothiolase
deficiency-caused dilated cardiomyopathies are among those.
While clinically infrequent, cardiac involvement may be
more common but obscured by physical inactivity imposed
by the associated skeletal muscle weakness. Nutritional de-
ficiencies are other causes of this type of cardiomyopathy.
Because these diseases are reversible, diagnosis is important
and possible with tracers of free fatty acids such as carbon-
11 palmitic acid combined with positron computed tomog-
raphy. Once the defect has been identified, replacement
therapy can be implemented and monitored with positron
computed tomography.
''Catecholamine cardiomyopathy" or "human stress car-
diomyopathy" is another form of dilated cardiomyopathy
in which victims of physical assault without internal or
cerebral injury may die suddenly or later of congestive heart
failure (43). A similar type of cardiac disease is an unusual
presentation of pheochromocytoma in children. In addition
to direct metabolic evaluation, in vivo assessment of cardiac
adrenergic receptors may be of benefit in the diagnosis and
management of these disorders. Other types of cardio-
myopathy with well established metabolic origins like hy-
poparathyroidism (44) and glycogen storage disorders like
Pompe's disease (45) may similarly benefit from metabolic
evaluations.
Duchenne's muscular dystrophy. Although we have
enumerated only a small number of intrinsic myocardial
diseases, many other cardiovascular disorders in infants and
children are likely to be associated with, aggravated by or
caused by metabolic disorders. The potential value of met-
abolic studies for diagnosis of disease can be illustrated by
an investigation recently completed in our laboratory. In-
fants with classic rapidly progressive X chromosome-linked
Duchenne's muscular dystrophy, a myopathic disorder ex-
isting from birth but usually remaining unrecognized until
the second year of life (46), were examined with positron
computed tomography and nitrogen-I 3 ammonia to evaluate
the distribution of blood flow and fluorine-18 2-fluoro 2-
deoxyglucose (FDG) to determine the regional utilization
of exogenous glucose (47). The disease targets the poster-
obasal portion of the left ventricle. The initial dystrophy in
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Future Use of Positron
Computed Tomography
Positron computed tomography as a tool for studying
body chemistry was conceived about 10 years ago (48).
Within 2 to 3 years of its inception, three groups were
actively pursuing research with this new study means. Since
then, the number of participating institutions and active
tomographs has grown steadily. By 1983, in the United
States and Canada alone, 17 institutions with a total of 27
scanners were actively utilizing positron computed tomog-
raphy. Progress abroad has been similar. A total of II tom-
ographs are operative in 10 institutions in Common Market
countries, with an additional 3 tomographs in 2 Scandi-
navian institutions. Implementation of positron computed
tomographic programs has been even more remarkable in
Japan where eight positron computed tomographs have been
installed and active research programs established at seven
institutions in the last 3 years. An additional 14 tomographs
are currently installed or have been ordered.
Roughly half of the available instruments are dedicated
brain tomographs with the other half general purpose ma-
chines. Positron computed tomographic research has been
most fruitful in the field of neurosciences with often as-
tounding, unique and clinically relevant results. Among these
are studies of normal brain physiology with delineation of
local metabolic responses to visual, auditory and cognitive
stimulation, investigations oforganic and affective disorders
such as Alzheimer's, Huntington's and Parkinson's disease,
epilepsy, stroke, schizophrenia and manic-depressive states
as well as investigations of the effects of drugs (30). Prog-
ress in the cardiac area has been less rapid for several rea-
sons. Because it is an asymmetrically located and moving
object, the heart is more difficult to image than the brain.
Hence, extraction of quantitative data is more complex. The
need to develop new tracer kinetic techniques (for example,
the definition and validation of the free fatty acid tracer
kinetic model) instead of adapting tracer kinetic models
already established in the neuroscieiltific area has been an
additional factor slowing application to the heart. Other
though equally important factors are the coarse spatial and
temporal resolution of early tomographs, which limits ex-
traction of quantitative information from the cross-sectional
images of the heart and the delineation of fast dynamic
Similarly, whether the observed metabolic abnormalities
antedated functional and blood flow abnormalities can only
be answered by follow-up studies. What is important, how-
ever, is that the observations lead to the formulation of a
working hypothesis that now can be tested and used to
further elicit the disease mechanism. Positron computed
tomography firmly established the existence of disease in
the majority of patients, disease that would have remained
undetected by conventional study techniques.
BA
L3
LI
L2
Figure 4. Three contiguous cross-sectional images (L1 to L3) of
the myocardial nitrogen-13 ammonia (A) and fluorine-18 2-fluoro
2-deoxyglucose (B) uptake in a 23 year old volunteer with Duch-
enne's muscular dystrophy. The heart is viewed from the patient's
feet. Note the decrease nitrogen-13 activity in the lateral wall (A,
arrows) associated with increased fluorine-18 2-f1uoro 2-deoxy-
glucose uptake (B, arrows).
this area later spreads to the free wall of the left ventricle
with relative sparing of the ventricular septum. The char-
acteristic though unspecific loss of posterobasal electric forces
oil the electrocardiogram was invariably present in all of
the 15 male infants and adolescents. Thallium-20l scintig-
niphy and radionuclide and echocardiographic left ventric-
ular functional studies disclosed segmental reductions in
blood flow in only three patients, and regional or global
ventricular dysfunction in only five patients. In contrast,
positron computed tomography revealed segmental reduc-
tions in nitrogen-13 ammonia uptake in 14 of 15 patients.
The affected segments were in II of 12 patients with suf-
ficient myocardial FDG uptake associated with increased
FDG accumulation (Fig. 4). Regional blood flow reductions
or defective metabolic trapping, or both, may have ac-
counted for the segmentally reduced nitrogen-13 ammonia
uptake, while the augmented FOG accumulation most likely
reflected enhanced utilization of exogenous glucose. Whether
the latter represented a regional compensatory shift in sub-
strate metabolism from free fatty acids to glucose to maintain
function awaits further studies with carbon-II palmitic acid.
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processes. With the emergence of a new generation of high
spatial and temporal resQlution tomographs with high count
rate detection efficiencies and multislice capabilities, these
limitations are largely resolved.
Costs. There are several factors that limit application of
positron computed tomography in general. Cost is foremost.
The short half-life of positron-emitting isotopes (ranging
from less than 2 minutes to several hours) requires an on-
site cyclotron and on-site synthesis of tracer substances, In
addition to the initial purchase price, current operating costs
are high. Other though important factors raising the cost of
positron computed tomographic procedures are home-build-
ing of many currently active tomographs with large technical
and engineering staffs, use of conventional physics cyclo-
trons with high staffing requirements and "manual" bio-
chemical synthesis of labeled tracer substances. Extensive
research and development programs in most institutions raise
the overhead cost even further. As it is in any early research
effort, direct extrapolation of these costs to a defined clinical
investigative program or diagnostic environment would,
therefore, seem inappropriate, Redirection of a program to
performing diagnostic studies exclusively with only two or
three tracers using existing equipment will dramatically re-
duce the cost per study. Another approach to cost reduction,
while retaining some of the specific advantages of positron
computed tomography, is reliance on tracers that do not
require on-site cyclotrons. The generator-produced blood
flow tracer rubidium-82 and fluorine-I 8 2-fluoro 2-deoxy-
glucose (FDG) are good examples. Although fluorine-I 8 is
cyclotron-produced, its 2 hour physical half-life allows dis-
tribl./tion of the tracer over greater geographic distances,
About 10 years ago, fluorine-18 was distributed for use as
a bone scanning agent in clinical nuclear medicine. The
pra~ticality of this approach for FDG has been proven on
the East Coast, where the tracer is delivered from Brook-
haven National Laboratory to Boston, New York, Phila-
delphia and Washington, D.C.
Other developments may provide far more practical cost
reductions. Design and production of dedicated medical cy-
clotrons is well underway; six dedicated medical "baby
cyclotrons" produced in Japan are already in operation. An
increasing number of commercial suppliers will compete for
sales of high performance positron tomographs. Private and
institutional efforts in the radiopharmaceutical sectors are
equally impressive. Semiautomated production of the most
frequently used tracers (FDG, carbon-II palmitic acid and
nitrogen-13 or carbon-II amino acids) has been accom-
plished and is now performed routinely. The next step to
the supply of positron-labeled compounds is the develop-
ment and integration of simple, single particle, low energy
minicyclotrons with automated or semiautomated chemical
synthesis techniques integrated into a single system operated
by a technician through a video terminal to provide a cost-
effective and efficient means for routine preparation of la-
beled compounds. These developments and innovations will
dramatically lower the operational cost of positron computed
tomography, Obviously, the initial purchase cost will re-
main high, although considerably lower than that of today's
cyclotrons. However, amortization of the cost of initial
equipment purchase over longer time, periods together with
low operation and building costs and in house radiophar-
maceutical production (instead of purchasing expensive ra-
dioisotopes such as iodine-123 or thallium-lOl) are impor-
tant for estimating the cost of ppsitron computed tomographic
studies.
Although high technology instrumentation is often high-
lighted as a major cost factor, comparisons are valid only
if the initial cost of an instrument together with the operating
expenses are compared with other costs over a time equiv-
alent to the lifetime of the instrument or on a yearly depre-
ciated schedule, One cal) compare, for example, in house
production of positron-emittin~tracers by the earlier men-
tioned semiautomated synthesis system with the clinical use
of thallium-20 I or iodine-l 23-labeled fatty acid tracers. Per
procedure, the cost for thallium-20 I is about $120 and for
iodine-123 about $189, For three procedures a day over a
10 year period witqout accounting for inflation, this
amounts to approximately $0,94 million for thallium-201
and $1.48 million for iodine-I 23 . If we add a 7% yearly
inflation rate, these values increase to $2.04 and $1.3 mil-
lion, respectively. These amounts are comparable with the
approximately $0.5 to $1 million estimated pl.lrchase cost
of the minicyclotron-based synthesis system. In regard to
the cost of the tomograph, if we consider X-ray computed
tomography, only about 10% of the actual patient charge
accounts for the purchase of the instrument and its service
cost. Thus, the manner in which relative cost factors are
determined must be considered more carefully, If this is
done, the cost of diagnostic positron computed tomographic
studies will be comparable with those of other noninvasive
diagnostic procedures,
Technologic problems. There are other factors related
to the long-term development of this technology. The min-
icyclotron unit is an electronic device that is tuned and
available as required. The tracers are typically labeled nat-
ural compounds or their analogs on which 20 to 50 years
of research knowledge provides a fundamental basis for
developing their use and for gaining Food and Drug Admin-
istration approval for human use (that is, they are not new
compounds for which enormous effort and time are required
to generate data to prove their safety), Complications of
federal transport and waste disposal are avoided because the
radionuclides are produced on site and their short half-life
causes them to rapidly decay. The ratio of data gathering
to patient radiation exposure time is high. This technology
provides <tn ever expanding number of labeled biologically
active compounds to probe the biochemical basis of human
disease and its treatment.
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Conclusions. With these technologic developments and
cost considerations, positron computed tomography is likely
to become a clinically invaluable tool. It is suited for ex-
ploring and characterizing a still largely unexplored area in
human physiology and disease, that is, regional myocardial
metabolism and its derangements in disease. Because dis-
ease begins at the biochemical level, often early d\lring life,
positron computed tomography is likely to significantly con-
tribute to the diagnosis, characterization and management
of cardiovascular disease in the young.
We are grateful to M. Lee Griswold for preparing the illustrations, Kerry
Engber for skillful secretarial assistance and Patrick Welton for editing the
manuscript.
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